New Regional President Announced for MSD in Asia Pacific
February 7, 2022 11:00 am Asia/Singapore
SINGAPORE, February 7, 2022 – MSD (NYSE: MRK), a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., announced that David Peacock has been appointed President of its Human Health Division in Asia Pacific from February 1, 2022. Combining all business divisions, MSD in Asia Pacific has approximately 6,000 employees across 12 key markets.1
David brings a broad range of experience and perspectives from senior roles in the United Kingdom, United States, and across Asia. Most recently, David was the Managing Director for MSD in the United Kingdom and Ireland. Prior to that, he was the Chief of Staff to Kenneth C. Frazier, former Chairman of the board and Chief Executive Officer, Merck & Co., Inc., Kenilworth, N.J. (known as MSD outside the U.S. and Canada). David has also held other significant roles such as Managing Director for MSD in Hong Kong and Macau, and Chief Financial Officer for MSD in Japan.
David said, “I am excited to return to Asia, a diverse and vibrant region. Asia also presents some of the world’s toughest healthcare challenges, and I am looking forward to working with our teams to build on existing partnerships and establishing new ones so that our innovative medicines and vaccines reach as many patients as possible.”
As we work through the COVID-19 pandemic, MSD will remain focused on discovering and developing innovative medicines and vaccines and working to enable access to these medical inventions to improve population health and save and improve lives.
MSD has a wide footprint in Singapore, bringing together all of MSD’s business divisions ranging from Manufacturing, R&D, Human Health’s commercial operations, Animal Health, an IT Hub and our Asia Pacific Regional Headquarters — a unique microcosm of our global business that enshrines Singapore’s ambitions as a node for technology, innovation, and enterprise.
For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing healthcare access through far-reaching policies, programs, and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as COVID-19, HIV, and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-singapore.com and connect with us on Twitter, LinkedIn, and YouTube.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA.
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).